化合物YQ128
中文名称 | 化合物YQ128 |
---|---|
中文同义词 | 化合物YQ128 |
英文名称 | YQ128 |
英文同义词 | 3-Thiopheneacetamide, N-[(5-chloro-2-propoxyphenyl)methyl]-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]-;N-[(5-chloro-2-propoxyphenyl)methyl]-N-(2-{4-[(pr op-2-yn-1-yl)sulfamoyl]phenyl}ethyl)-2-(thiophen- 3-yl)acetamide;YQ128;YQ128,inhibit,YQ 128,Inhibitor,NOD-like Receptor (NLR),Interleukin Related,YQ-128 |
CAS号 | 2454246-18-3 |
分子式 | C27H29ClN2O4S2 |
分子量 | 545.11 |
EINECS号 | |
相关类别 | |
Mol文件 | 2454246-18-3.mol |
结构式 |
化合物YQ128 性质
沸点 | 705.8±70.0 °C(Predicted) |
---|---|
密度 | 1.287±0.06 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:250 mg/ml(458.62 mM) |
形态 | 结晶固体 |
酸度系数(pKa) | 9.32±0.50(Predicted) |
颜色 | 白色至米白色 |
NLRP3 0.30 μM (IC 50 ) |
IL-1β
|
YQ128 (0.3-100 µM; 30 mins) dose dependently suppressed the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge with an IC
50
of 1.59 µM.
YQ128 (20 µM; 2 hours) shows no significant toxic effects on hCMEC/D3 cells.
Cell Viability Assay
Cell Line: | Mouse peritoneal macrophages |
Concentration: | 0.3, 1.0, 3.0, 10, 30, 100 µM |
Incubation Time: | 30 mins |
Result: | Suppressed the release of IL-1β from peritoneal macrophages upon LPS/ATP challenge with an IC 50 of 1.59 µM. |
YQ128 (iv; 20 mg/kg) has an intermediate terminal plasma half-life (t
1/2
) of 6.6 hours after iv administration.
YQ128 (oral; 20 mg/kg) shows delayed gastrointestinal absorption with a t
max
and c
max
of 12 h and 73 ng/mL, respectively. Oral bioavailability (F
oral
) is estimated as 10%.
YQ128 exhibits extensive extravascular distribution with a large steady-state volume of distribution (Vd
ss
) of 8.5 L/kg and rapid total clearance (CL
tot
) of 41 mL/min/kg.
YQ128 (10 mg/kg) has been shown to trigger IL-1β production in a NLRP3- dependent manner in C57BL/6 mice.
Animal Model: | Sprague-Dawley rats (200-250 g) |
Dosage: | 20 mg/kg (Pharmacokinetic Analysis) |
Administration: | Iv |
Result: | Had an intermediate terminal plasma half-life (t 1/2 ) of 6.6 hours after iv administration. |